Marc Brannigan

The Weekly Brief
The best of SHOWSIGHT editorials, weekly wins, and breeder commentary — delivered to your inbox every Sunday morning.
You would never breed to a dog whose pedigree you couldn’t see.
You’d want the papers. You’d want to know what’s behind the sire and what’s behind the dam, what the line has produced, and what it has thrown that nobody brings up at the banquet. “He’s a nice dog” is not documentation.
And yet a great many people in this sport are giving their dogs a hemp product chosen off a shelf on the strength of a number on the front of a bottle and a photograph of a dog in a field. No pedigree. No idea what’s behind it.
That isn’t a knock on anyone’s judgment. It’s what happens when a plant vanishes from American agriculture for eighty years, then comes roaring back into a market nobody had time to organize.
Hemp and marijuana are not two plants. They are one species—Cannabis sativa L.—separated by a legal threshold, not a botanical wall. Both produce the same family of cannabinoids. A CBD molecule has no idea which side of the line the plant it came from was standing on.
So, if they aren’t different plants, what makes them different?
Breeding. Nothing else. Same species, same cannabinoid toolbox, radically different ratios—and ratios are precisely what selection controls.
Put a field-bred line beside a line campaigned in the ring for sixty years. Same breed on paper, six decades of divergent selection standing in front of you. That is the hemp story.
When the AKC was founded in 1884, hemp was an ordinary American farm crop grown for fiber and seed, and resin was a nuisance that gummed up the harvest. Your great-great-grandfather’s hemp field would have made terrible oil. Nobody was trying to make oil. Then the 1937 Marihuana Tax Act ended the crop—five years before the USDA, short of rope in wartime, put out a film begging farmers to plant it again. The knowledge went with it regardless. No stud books. No breeding records.
When a breed loses careful record-keeping for even a single generation, the damage takes decades to undo. Hemp is an annual. It lost eighty generations.
The 2018 Farm Bill made it legal again, and the plant that came back is not the plant that left. Beginning around 2014, breeders selected hard for something no fiber farmer had ever wanted: resin.
Same species. Same word on the label. Different animal.
Three dogs come up more than any others, and the first one comes up most.
The veteran with joint pain. The dog who thinks about the stairs before he takes them, who needs a minute to loosen up on a cold morning, who still wants the job but pays for it the next day. Osteoarthritis is an inflammatory problem at bottom, and inflammation is where most of the serious interest in cannabinoids for dogs has settled.
I have an interest to declare here. A ninety-day trial of a cannabidiol-rich hemp oil in dogs with osteoarthritis-related pain was run with Colorado State University and overseen by Dr. Robin Downing, who in 2005 became only the third veterinarian in the world credentialed as a Diplomate of the American Academy of Pain Management, and who founded the International Veterinary Academy of Pain Management. Thirty-two dogs completed it. Thirty improved. It was published in the Journal of the American Holistic Veterinary Medical Association in 2020.
My company supplied the oil for that trial and covered clinic costs. We had no hand in designing it, running it, or interpreting the results, and the authors hold no financial relationship with us—all of it stated in the journal. A pilot study of thirty-two dogs is a beginning and not a proof. But ninety days is a long look at an old dog, and considerably longer than most of what has been published.
A separate randomized, placebo-controlled trial at Cornell got to the same place by a different road, dosing at 2 mg/kg twice daily: less pain and more activity, measured at two weeks and again at four. The owners noticed. So did the veterinarians scoring them.
The dog with skin issues who will not leave his own feet alone —chewing, scratching, rubbing his face along the furniture. Published work on dogs with atopic dermatitis has been encouraging enough that veterinary dermatologists are running the trials themselves. Skin is also the one place a topical earns its keep: a balm worked into a hot spot or a cracked pad, rather than an oil by mouth.
The dog with generalized anxiety who comes apart in a thunderstorm, or in the crate on the third night of a circuit. One study of dogs facing separation and car travel found measurable improvement in stress markers. Another, using a fireworks recording, found none—though those dogs were tested hours after dosing, well past the window when CBD peaks in the blood. Promising, not yet settled.
Form matters nearly as much as dose. Oils are the workhorse and the easiest to measure and adjust. Chews are simpler on the road and at a show, at the cost of some precision. Balms and salves go where the problem is and stay there.
Most of the published work sits in the neighborhood of 2 mg per kilogram twice daily, which is a good deal more than the label on many bottles suggests. Start lower than that, give it with food—these compounds are fat-soluble and absorb far better alongside a meal—and hold a dose for a week or two before deciding it isn’t working. Almost every trial that measured anything measured it at two weeks or later. The most common mistake is not too much; it’s too little, for too short a time, and then giving up.
Sedation and loose stool are the usual signs you have gone too high. Both resolve on their way back down.
One sensible step, and it matters more with an old dog than a young one: talk to your veterinarian before you add hemp on top of anything a dog is already taking.
Cannabinoids are not the only thing in the plant. Cannabis also produces terpenes, flavonoids, and other compounds in very small concentrations, and small concentrations are not the same as small consequences. Beta-caryophyllene—the peppery note in black pepper and cloves—binds the CB2 cannabinoid receptor outright; the 2008 paper in the Proceedings of the National Academy of Sciences is titled, flatly, “Beta-caryophyllene is a dietary cannabinoid.” Whether the whole profile outperforms its isolated parts is still being worked out. That it is worth protecting is not.
Which raises the only question that matters, and it is not the one printed on the front of the bottle.
The plant’s identity comes from breeding. The oil’s identity comes from six decisions made afterward: the genetics, how it was grown, how it was harvested, whether it was fast-dried or properly cured, how it was extracted, and whether what survives is full spectrum, broad spectrum, or isolate.
Every one of those is a place where the supporting cast can be lost. Terpenes are volatile—heat and haste drive them off. Harsh extraction strips them. Isolate discards the orchestra to keep a single instrument.
Six links. Any one of them can be the weak one. None of them appear on the label.
We’ll take those six one at a time in the issues ahead—what curing actually does, how to read a certificate of analysis without a chemistry degree, what full spectrum and broad spectrum and isolate really mean, and what the research does and does not yet show in dogs.
On that last point, this sport’s own health foundation already has a stake: the AKC Canine Health Foundation has supported canine cannabidiol research.
For now, one question is enough, and it is the same question you would ask about a dog.
Not “what is it?”—but “what’s behind it?”
Nobody chooses a wine by reading the alcohol percentage.
That is exactly how most people buy hemp oil.

American Kennel Club (AKC)
The AKC has introduced a new policy and disciplinary measures aimed at protecting dogs and strengthening safety standards at AKC events.